| CKDXF Stock | | | USD 0.44 0.00 0.00% |
Director
Dr. Ian Leitch serves as Director Clinical Research of Circadian Technologies Ltd since September 12, 2011. He has over 15 years of research and management experience from drug discovery through clinical development in biotechnologypharmaceutical companies. For the five years prior to joining Circadian, he was a member of the Medical Sciences group at Amgen Inc in Thousand Oaks, California, involved in the development of novel therapeutics in Amgens oncology pipeline. In his role as Senior Manager in the Early Development Oncology Therapeutic Area, he had responsibility for the oversight, design, management and execution of Phase III clinical studies in oncology. Prior to joining Amgen, he spent eight years at Miravant Medical Technologies in Santa Barbara, California. He held positions of increasing responsibility, including Senior Program Manager for Cardiovascular Research and Clinical Study Director for Ophthalmology. At Miravant he managed preclinical efficacy studies, developed relationships with Key Opinion Leaders and designed Phase III clinical studies in collaboration with the cardiovascular device company Guidant Inc. He previously held the position of NHMRC Senior Research Officer at the University of Newcastle, and was based at the John Hunter Hospital in Australia. He received his PhD from the Department of Pharmacology, Faculty of Medicine, at Monash University in 1993 and completed part of the degree at the University of California, Santa Barbara, as part of an Education Abroad Program Scholarship. since 2011.
| Age | 60 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 61 3 9826 0399 |
| Web | https://opthea.com |
Opthea Management Efficiency
The company has return on total asset
(ROA) of
(0.6081) % which means that it has lost $0.6081 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.0129) %, meaning that it generated substantial loss on money invested by shareholders. Opthea's management efficiency ratios could be used to measure how well Opthea manages its routine affairs as well as how well it operates its assets and liabilities.
Similar Executives
| Found 1 records | DIRECTOR Age |
| Frederic MD | Immutep Ltd ADR | 69 |
Opthea [CKDXF] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Opthea Leadership Team
Elected by the shareholders, the Opthea's board of directors comprises two types of representatives: Opthea inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opthea. The board's role is to monitor Opthea's management team and ensure that shareholders' interests are well served. Opthea's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opthea's outside directors are responsible for providing unbiased perspectives on the board's policies.
Opthea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Opthea a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Opthea Pink Sheet
When determining whether Opthea is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Opthea Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Opthea Stock.
Highlighted below are key reports to facilitate an investment decision about Opthea Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Opthea. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in interest.
For more detail on how to invest in Opthea Pink Sheet please use our
How to Invest in Opthea guide.
You can also try the
Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Please note, there is a significant difference between Opthea's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opthea is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opthea's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.